MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
July 29, 2026
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board
January 25, 2022
Related Post
-
-
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
July 27, 2026
-
NorthStrive Defense Tech Engages Defense Software and Security Firm Deploy360 to Validate Patented GPS-Denied Drone Navigation Technology Under Option to License
July 27, 2026
-
MannKind Announces FDA Approval of Furoscix ReadyFlow(TM), the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
July 24, 2026